2020
Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Dosoretz A, Shafman T, Gross C, Yu J, Meadows H, Decker R, Mak R, Kann B. Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e90. DOI: 10.1016/j.ijrobp.2020.07.1190.Peer-Reviewed Original ResearchQuantifying Treatment Selection Bias Effects on Survival in National Database Studies: Findings from Low-Risk Prostate Cancer Patients
Miccio J, Talcott W, Jairam V, Park H, Yu J, Leapman M, King M, Nguyen P, Kann B. Quantifying Treatment Selection Bias Effects on Survival in National Database Studies: Findings from Low-Risk Prostate Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e397. DOI: 10.1016/j.ijrobp.2020.07.2439.Peer-Reviewed Original ResearchQuantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient managementThe Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer.
Hsiang W, Han X, Jemal A, Nguyen KA, Shuch B, Park H, Yu JB, Gross CP, Davidoff AJ, Leapman MS. The Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer. Urology Practice 2020, 7: 252-258. PMID: 34017908, PMCID: PMC8130174, DOI: 10.1097/upj.0000000000000109.Peer-Reviewed Original ResearchGerm cell tumorsTesticular germ cell tumorsProportion of patientsAffordable Care ActNon-expansion statesNational Cancer Data BaseExpansion statusState Medicaid expansion statusTesticular cancer patientsAdvanced-stage cancerLate-stage diagnosisLow-income patientsHealth insuranceCare ActMedicaid expansion statesMedicaid expansion statusDisease stageCancer patientsInsurance statusTesticular cancerCell tumorsPost-ACAMedicaid coveragePatientsMedicaid expansion
2019
An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Kann B, Dosoretz A, Shafman T, Gross C, Yu J, Decker R. An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s145-s146. DOI: 10.1016/j.ijrobp.2019.06.146.Peer-Reviewed Original ResearchEmergency department visits for prescription and synthetic opioid overdoses among patients with cancer.
Jairam V, Yang D, Yu J, Park H. Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer. Journal Of Clinical Oncology 2019, 37: 6579-6579. DOI: 10.1200/jco.2019.37.15_suppl.6579.Peer-Reviewed Original ResearchED visitsOpioid overdoseEmergency departmentHigh riskOverdose ratesCervical cancerSynthetic opioidsUtilization Project Nationwide Emergency Department SampleNationwide Emergency Department SampleNon-cancer patientsEnd Results ProgramEmergency Department SampleIntrahepatic bile ductsPrimary cancer siteSynthetic opioid overdoseDiagnosis of cancerRespiratory intubationMetastatic diseaseHospital admissionOpioid dependencePrimary cancerBile ductResults ProgramCancer patientsCommon cancerTumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).
Sperduto P, Mesko S, Cagney D, Nesbit E, Chan J, Lee J, Breen W, Shi D, Soliman H, Shanley R, Everett A, Masucci L, Remick J, Plichta K, Jain S, Wu C, Bryant J, Yu J, Nakano T, Mehta M. Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA). Journal Of Clinical Oncology 2019, 37: 1079-1079. DOI: 10.1200/jco.2019.37.15_suppl.1079.Peer-Reviewed Original ResearchBrain metastasesPrognostic factorsMedian survivalTumor subtypesBreast cancer patientsBreast-GPAExtracranial metastasesCohort ALuminal BLuminal AImproved survivalCancer patientsComplication of breast cancerKaplan-Meier survival estimatesBrain radiation therapyLog-rank testRadiation therapyBasal tumorsPrognostic indexCohort BFatal complicationRetrospective databaseTreatment patternsPrognostic assessmentBreast cancer
2017
Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study
Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert B, Vieites B, Limon D, Kurman N, Ko K, Yu J, Chiang V, Poortmans P, Zagar T. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research And Treatment 2017, 167: 479-483. PMID: 28975433, DOI: 10.1007/s10549-017-4526-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSubsequent brain metastasesHuman epidermal growth factor receptor 2Brain metastasesCancer patientsEthical research committeeReceptor statusPrimary tumorProgesterone receptorEstrogen receptorEpidermal growth factor receptor 2Triple-negative profileGrowth factor receptor 2Primary breast cancerPrimary breast tumorsInternational multicenter studyFactor receptor 2Multicenter studyAvailable histologyResultsA totalBreast cancerReceptor 2ConclusionsThe majorityPatientsBreast tumors
2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original ResearchEmerging Technologies and Techniques in Radiation Therapy
Magnuson W, Mahal A, Yu J. Emerging Technologies and Techniques in Radiation Therapy. Seminars In Radiation Oncology 2016, 27: 34-42. PMID: 27986210, DOI: 10.1016/j.semradonc.2016.08.004.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyHigh-dose-rateProton beam radiationRadiation therapyProstate cancerHigh-dose-rate (HDR) brachytherapyHigh-risk prostate cancer patientsHigh-risk prostate cancerTreatment of prostate cancerPartial gland treatmentProstate-directed therapyRegional radiation therapyLow-risk diseaseBeam radiationProstate cancer patientsDeliver radiationImprove cancer controlHigh-intensity focused ultrasoundFocal therapyTherapeutic modalitiesRadiation treatmentCancer patientsCancer controlTherapyReduced toxicityChanges in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy
Wang E, Wang S, Soulos P, Chen R, Kim S, Gross C, Yu J. Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. Journal Of Radiation Oncology 2016, 6: 295-300. DOI: 10.1007/s13566-016-0269-0.Peer-Reviewed Original ResearchExternal beam radiation therapyIntensity-modulated radiation therapyMental component scoreRadiation therapyProstate cancerEnd Results-Medicare Health Outcomes SurveyEra of IMRTComponent scoresImproved health-related qualityNonmetastatic prostate cancerPhysical component scoreHealth-related qualityHealth Outcomes SurveyStandard of careProstate cancer patientsExternal beam radiotherapyBeam radiation therapyQuality of lifeMethodsThe SurveillanceElderly patientsHRQOL measurementCancer patientsOutcome SurveyBeam radiotherapyLater eraDigital health application for real-time patient-reported outcomes during prostate radiotherapy.
Yang D, Thea J, An Y, Yu J. Digital health application for real-time patient-reported outcomes during prostate radiotherapy. Journal Of Clinical Oncology 2016, 34: 157-157. DOI: 10.1200/jco.2016.34.2_suppl.157.Peer-Reviewed Original ResearchPatient-reported outcomesQuality of lifeProstate radiotherapyTreatment periodExpanded Prostate Index CompositeClinical practice surveyDaily radiation treatmentsGenitourinary Cancers SymposiumFuture prospective studiesProstate cancer patientsClinical trial dataPatient Data CollectionPaucity of dataClinical research toolCancer SymposiumRoutine followPatient reportingProspective studySingle institutionCancer patientsClinical trialsSide effectsQOL domainsPatientsTrial data
2015
Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study
Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study. Blood 2015, 126: 3295. DOI: 10.1182/blood.v126.23.3295.3295.Peer-Reviewed Original ResearchMDS/AMLProstate cancer patientsIntensity-modulated radiotherapyProstate cancer diagnosisImpact of radiotherapyCancer patientsMyelodysplastic syndromeProstate cancerMyeloid malignanciesSecond malignanciesHazard ratioCancer diagnosisRadiation modalitiesEnd Results-Medicare databaseElderly prostate cancer patientsRisk of MDSMultivariate modelRetrospective cohort studyRole of radiotherapyElixhauser comorbidity scoreAcute myeloid leukemia diagnosisHistory of anemiaAcute myeloid leukemiaEnd of studyExternal beam radiotherapySecondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study
Zeidan A, Long J, Wang R, Yu J, Hall J, Abel G, Gore S, Gross C, Ma X, Davidoff A. Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. Blood 2015, 126: 1676. DOI: 10.1182/blood.v126.23.1676.1676.Peer-Reviewed Original ResearchTherapy-related myeloid neoplasmsMDS/acute myeloid leukemiaSingle-modality radiotherapyAcute myeloid leukemiaBreast cancer patientsMonths of diagnosisEarly breast cancerCompeting-risk analysisMyelodysplastic syndromeBreast cancerCancer patientsBreast cancer diagnosisRisk factorsMyeloid neoplasmsRadiation therapyAML/myelodysplastic syndromeFemale breast cancer patientsNational Cancer Institute's SurveillanceRadiotherapy-treated patientsReceipt of radiotherapySecondary myeloid neoplasmsRetrospective cohort studyCancer diagnosisNumber of comorbiditiesBetter overall survival80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY
Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY. Leukemia Research 2015, 39: s39. DOI: 10.1016/s0145-2126(15)30081-3.Peer-Reviewed Original Research
2013
The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit
Raldow A, Presley C, Yu J, Cramer L, Soulos P, Long J, Makarov D, Gross C. The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s177-s178. DOI: 10.1016/j.ijrobp.2013.06.459.Peer-Reviewed Original Research
2012
Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.
Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.Peer-Reviewed Original ResearchProstate cancer patientsSix monthsShort-term toxicityOne-yearCancer patientsPRT patientsProstate cancerProton radiotherapyLogistic regressionTreatment-related complicationsOne-year outcomesCumulative complication rateMultivariable logistic regressionPatient-reported outcomesPatterns of careConditional logistic regressionHigher socioeconomic statusGU complicationsGU toxicityComplication rateEarly toxicityDiagnosis codesLong-term effectsRadiation therapyMedicare populationThe influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.Peer-Reviewed Original ResearchHealth system factorsHealth service areasCurative therapyUrologist densityClinical benefitProstate cancerRadiation oncologistsPhysician densitySystem factorsRadiation oncologist densityEnd Results (SEER) databaseLower likelihoodReceipt of treatmentMarital statusProstate cancer patientsHigher likelihoodLogistic regression modelsArea Resource FilePatient characteristicsPatient factorsInitial treatmentResults databasePatient populationCancer patientsProper therapy
2011
The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit
Aneja S, Makarov D, Gross C, Roberts K, Yu J. The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s553. DOI: 10.1016/j.ijrobp.2011.06.871.Peer-Reviewed Original ResearchRadiation oncologist density and pancreatic cancer mortality.
Aneja S, Yu J. Radiation oncologist density and pancreatic cancer mortality. Journal Of Clinical Oncology 2011, 29: 350-350. DOI: 10.1200/jco.2011.29.4_suppl.350.Peer-Reviewed Original ResearchPC mortalityPancreatic cancerRadiation oncologistsCurative treatmentCancer mortalityTreatment of PCRadiation oncologist densityPancreatic cancer mortalityEsophageal cancer mortalityHealth care facilitiesArea Resource FileMultidisciplinary careCancer RegistryColorectal cancerCancer patientsPC outcomesMultivariate regression modelCare facilitiesU.S. CentersMortalityDisease controlSignificant financial relationshipSocioeconomic statusRadiation oncologyResource File